Metformin as Host-Directed Therapy for TB Treatment: Scoping Review
Abstract
Tuberculosis disease caused by Mycobacterium tuberculosis remains a global health concern. Evolution of multi-drug resistant strains may cause bacterial persistence, rendering existing antibiotics ineffective. Hence, development of new or repurposing of currently approved drugs to fight Mycobacterium tuberculosis in combination with existing antibiotics is urgently needed to cure tuberculosis which is refractory to current therapy. Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment duration and reduce lung injury by attenuating host mechanisms that cause lung inflammation. The range of potential candidates is broad, and includes several agents approved for the treatment of other diseases. One potential candidate is metformin, an FDA-approved drug used to treat type 2 diabetes mellitus. However, there is a scarcity of evidence supporting the biological basis for the effect of metformin as host-directed therapy for tuberculosis. This scoping review summarizes the current body of evidence and outlines scientific gaps that need to be addressed in determining the potential role of metformin as host directed therapy.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.